STENTYS

Revenues for the 4th quarter of 2011

- **Continued top line growth**
- **Solid cash position**
- **Numerous key developments expected in 2012**

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only *self-apposing stent* to treat Acute Myocardial Infarction (AMI), today reports its revenues for the 4th quarter and full year to 31 December 2011.

- **2011 revenues, quarterly and annual**

In € thousands*	2010**	2011
Q1	n/a	251.4
Q2	n/a	347.6
Q3	87.5	371.0
Q4	145.9	463.0
FY – 12 months	**305.6**	**1,432.0**

*unaudited
* * the Company did not draw up quarterly results prior to its IPO, so a comparison with the first half of 2010 cannot be made

Revenues for the 4th quarter of 2011 totalled €463.0k, an increase of 25% over the 3rd quarter of 2011 and more than triple the figure recorded over the 4th quarter of 2010. For its first full year of activity, STENTYS recorded annual revenues of €1.4 million.

STENTYS continued to benefit from the gradual ramping up of sales in the six new countries opened in 2011, which represented almost half (47%) of 4th quarter sales. The Company's self-apposing stent is currently in its pre-marketing phase in 8 European countries.

- **Solid cash position**

At 31 December 2011, STENTYS had a cash position of €14.7m, reflecting efficient cost control throughout 2011.

STNT
LISTED
NYSE
EURONEXT

- **2012, a year of many developments**

STENTYS expects numerous developments in 2012.

On the clinical side, the results of the international APPOSITION III clinical trial on 1,000 patients 30 days after being treated will be announced at the PCR congress in Paris in May. It should be noted that the Company has already presented, back in November 2011, outstanding interim results that further strengthen the medical value of STENTYS' self-apposing stents. The 12-month interim results are expected by the end of the year. Moreover, further studies will also be started, and in particular the APPOSITION IV clinical trial that will prove the superiority of the long-term apposition of STENTYS drug eluting stent compared to the current market leader.

In 2012, the Company expects to receive FDA (Food and Drug Administration) Investigational Device Exemption approval to carry out the APPOSITION V clinical trial in the US, a necessary first step to receive marketing authorisation in that country.

In terms of operations, STENTYS will continue its listing in the largest hospitals of the 8 currently open European countries. This market development will notably be carried out by organising post-market studies or registries, such as the OPEN II study on coronary lesions close to a bifurcation.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: "*We are very pleased with the progress achieved in 2011, in line with the business plan presented at the time of our IPO, and we are perfectly ready for this new pivotal year that should see FDA approval for the start of clinical trials in the United States and solid growth in revenues.*"

- **Next press release**

STENTYS will publish its 2011 annual results on 7 March 2012, after market.

About STENTYS:

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.
More information on www.stentys.com.

Stentys
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Financial Communication / Investor & Press Relations
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT